Kanyr Pharma
Kanyr Pharma was incorporated in May 2013 and is advancing innovative approaches to drug discovery in the protein tyrosine phosphatase (PTP) field. The company has acquired rights from McGill University to two major cancer programs, including a PRL-PTP inhibitor and the Immunyr™ technology, and is actively pursuing seed funding to support further development. Kanyr’s research team brings over 15 years of specialized experience in PTP research and is recognized as a leader in the chemical targeting of the PTP gene family. This family of enzymes is implicated in a wide range of human diseases and represents a largely untapped area of therapeutic opportunity.
Unique Opportunity
PTPs were long considered "undruggable," but recent scientific advances have demonstrated that they can be successfully targeted, opening a new frontier in drug discovery. Today, the PTP inhibitor field is at a stage comparable to where kinase inhibitors were two decades ago—before they became a cornerstone of modern cancer therapy. Kanyr Pharma is well positioned to capitalize on this emerging opportunity through three broadly applicable oncology programs: PTP inhibitor immunotherapy, the proprietary Immunyr™ technology platform, and PRL-PTP inhibitors.